Jie Zhou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3807415/publications.pdf

Version: 2024-02-01

258	72,881	95	251
papers	citations	h-index	g-index
272	272	272	94786
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	A(H1N1)pdm09 Influenza Viruses Replicating in Ferret Upper or Lower Respiratory Tract Differed in Onward Transmission Potential by Air. Journal of Infectious Diseases, 2022, 225, 65-74.	4.0	9
2	Low Environmental Temperature Exacerbates Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Golden Syrian Hamsters. Clinical Infectious Diseases, 2022, 75, e1101-e1111.	5.8	17
3	SPINK6 inhibits human airway serine proteases and restricts influenza virus activation. EMBO Molecular Medicine, 2022, 14, e14485.	6.9	5
4	Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature, 2022, 603, 693-699.	27.8	460
5	Mutations that adapt SARS-CoV-2 to mink or ferret do not increase fitness in the human airway. Cell Reports, 2022, 38, 110344.	6.4	46
6	hnRNP C modulates MERS-CoV and SARS-CoV-2 replication by governing the expression of a subset of circRNAs and cognitive mRNAs. Emerging Microbes and Infections, 2022, 11, 519-531.	6.5	8
7	SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerging Microbes and Infections, 2022, 11, 277-283.	6.5	308
8	Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature, 2022, 602, 676-681.	27.8	1,038
9	Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients. Clinical Infectious Diseases, 2022, 75, e822-e826.	5.8	322
10	Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Subvariant BA.2 in a Single-Source Community Outbreak. Clinical Infectious Diseases, 2022, 75, e44-e49.	5.8	66
11	Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nature Medicine, 2022, 28, 1031-1041.	30.7	281
12	Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants. Emerging Microbes and Infections, 2022, 11, 926-937.	6.5	16
13	Establishing Human Lung Organoids and Proximal Differentiation to Generate Mature Airway Organoids. Journal of Visualized Experiments, 2022, , .	0.3	6
14	Animal models in SARS-CoV-2 research. Nature Methods, 2022, 19, 392-394.	19.0	51
15	Targeting papain-like protease for broad-spectrum coronavirus inhibition. Protein and Cell, 2022, 13, 940-953.	11.0	23
16	A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model. Vaccine, 2022, 40, 2848-2855.	3.8	7
17	Interferon-gamma inhibits influenza A virus cellular attachment by reducing sialic acid cluster size. IScience, 2022, 25, 104037.	4.1	10
18	Broad-spectrum Respiratory Virus Entry Inhibitors. Advances in Experimental Medicine and Biology, 2022, 1366, 137-153.	1.6	2

#	Article	IF	Citations
19	Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals., 2022, 19, 588-601.		27
20	Bacillus Calmette-Guérin–induced trained immunity protects against SARS-CoV-2 challenge in K18-hACE2 mice. JCI Insight, 2022, 7, .	5.0	29
21	An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron. Nature Microbiology, 2022, 7, 716-725.	13.3	62
22	Pathogenicity of SARSâ€CoVâ€2 Omicron. Clinical and Translational Medicine, 2022, 12, e880.	4.0	12
23	Response to Evidence in favor of the essentiality of human cell membrane-bound ACE2 and against soluble ACE2 for SARS-CoV-2 infectivity. Cell, 2022, 185, 1840-1841.	28.9	3
24	Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters. Science, 2022, 377, 428-433.	12.6	113
25	A bipotential organoid model of respiratory epithelium recapitulates high infectivity of SARS-CoV-2 Omicron variant. Cell Discovery, 2022, 8, .	6.7	28
26	A trifunctional peptide broadly inhibits SARS-CoV-2 Delta and Omicron variants in hamsters. Cell Discovery, 2022, 8, .	6.7	7
27	Investigating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Surface and Air Contamination in an Acute Healthcare Setting During the Peak of the Coronavirus Disease 2019 (COVID-19) Pandemic in London. Clinical Infectious Diseases, 2021, 73, e1870-e1877.	5.8	227
28	Natural Transmission of Bat-like Severe Acute Respiratory Syndrome Coronavirus 2 Without Proline-Arginine-Arginine-Alanine Variants in Coronavirus Disease 2019 Patients. Clinical Infectious Diseases, 2021, 73, e437-e444.	5.8	62
29	SARS-CoV-2 Induces a More Robust Innate Immune Response and Replicates Less Efficiently Than SARS-CoV in the Human Intestines: An ExÂVivo Study With Implications on Pathogenesis of COVID-19. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 771-781.	4.5	41
30	STAT2-dependent restriction of Zika virus by human macrophages but not dendritic cells. Emerging Microbes and Infections, 2021, 10, 1024-1037.	6.5	12
31	<i>In silico</i> structure-based discovery of a SARS-CoV-2 main protease inhibitor. International Journal of Biological Sciences, 2021, 17, 1555-1564.	6.4	12
32	Development of Three-Dimensional Human Intestinal Organoids as a Physiologically Relevant Model for Characterizing the Viral Replication Kinetics and Antiviral Susceptibility of Enteroviruses. Biomedicines, 2021, 9, 88.	3.2	15
33	Aptamer-targeting of Aleutian mink disease virus (AMDV) can be an effective strategy to inhibit virus replication. Scientific Reports, 2021, 11, 4649.	3.3	7
34	Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. Nature, 2021, 593, 418-423.	27.8	151
35	Host-derived lipids orchestrate pulmonary $\hat{I}^3\hat{I}^*T$ cell response to provide early protection against influenza virus infection. Nature Communications, 2021, 12, 1914.	12.8	22
36	Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2. Nature Communications, 2021, 12, 1517.	12.8	43

#	Article	IF	Citations
37	Human Intestinal Organoids Recapitulate Enteric Infections of Enterovirus and Coronavirus. Stem Cell Reports, 2021, 16, 493-504.	4.8	38
38	Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system. Cell, 2021, 184, 2212-2228.e12.	28.9	216
39	Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. Cell Host and Microbe, 2021, 29, 551-563.e5.	11.0	87
40	The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Nature Microbiology, 2021, 6, 899-909.	13.3	556
41	A new class of α-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities. European Journal of Medicinal Chemistry, 2021, 215, 113267.	5.5	13
42	Monocytic MDSC mobilization promotes tumor recurrence after liver transplantation via CXCL10/TLR4/MMP14 signaling. Cell Death and Disease, 2021, 12, 489.	6.3	37
43	Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model. PLoS Pathogens, 2021, 17, e1009527.	4.7	23
44	Favipiravir-resistant influenza A virus shows potential for transmission. PLoS Pathogens, 2021, 17, e1008937.	4.7	23
45	Targeting highly pathogenic coronavirus-induced apoptosis reduces viral pathogenesis and disease severity. Science Advances, 2021, 7, .	10.3	48
46	Inhaled Dry Powder Formulation of Tamibarotene, a Broadâ€Spectrum Antiviral against Respiratory Viruses Including SARSâ€CoVâ€2 and Influenza Virus. Advanced Therapeutics, 2021, 4, 2100059.	3.2	12
47	Intradermal vaccination of live attenuated influenza vaccine protects mice against homologous and heterologous influenza challenges. Npj Vaccines, 2021, 6, 95.	6.0	6
48	The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum. EBioMedicine, 2021, 71, 103544.	6.1	38
49	SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature, 2021, 599, 114-119.	27.8	1,041
50	Severe fever with thrombocytopenia syndrome virus (SFTSV)-host interactome screen identifies viral nucleoprotein-associated host factors as potential antiviral targets. Computational and Structural Biotechnology Journal, 2021, 19, 5568-5577.	4.1	3
51	Host and viral determinants for efficient SARS-CoV-2 infection of the human lung. Nature Communications, 2021, 12, 134.	12.8	112
52	Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerging Microbes and Infections, 2021, 10, 507-535.	6.5	202
53	Coinfection by Severe Acute Respiratory Syndrome Coronavirus 2 and Influenza A(H1N1)pdm09 Virus Enhances the Severity of Pneumonia in Golden Syrian Hamsters. Clinical Infectious Diseases, 2021, 72, e978-e992.	5.8	84
54	SARS-CoV-2 exploits host DGAT and ADRP for efficient replication. Cell Discovery, 2021, 7, 100.	6.7	29

#	Article	IF	CITATIONS
55	In Silico Structure-Based Design of Antiviral Peptides Targeting the Severe Fever with Thrombocytopenia Syndrome Virus Glycoprotein Gn. Viruses, 2021, 13, 2047.	3.3	0
56	Emerging SARS-CoV-2 variants expand species tropism to murines. EBioMedicine, 2021, 73, 103643.	6.1	127
57	Activation of C-Type Lectin Receptor and (RIG)-I-Like Receptors Contributes to Proinflammatory Response in Middle East Respiratory Syndrome Coronavirus-Infected Macrophages. Journal of Infectious Diseases, 2020, 221, 647-659.	4.0	43
58	Oral SARS-CoV-2 Inoculation Establishes Subclinical Respiratory Infection with Virus Shedding in Golden Syrian Hamsters. Cell Reports Medicine, 2020, 1, 100121.	6.5	121
59	Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature, 2020, 586, 113-119.	27. 8	672
60	Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. Nature Microbiology, 2020, 5, 1439-1448.	13.3	140
61	Human coronavirus dependency on host heat shock protein 90 reveals an antiviral target. Emerging Microbes and Infections, 2020, 9, 2663-2672.	6.5	46
62	Middle East Respiratory Syndrome Coronavirus ORF8b Accessory Protein Suppresses Type I IFN Expression by Impeding HSP70-Dependent Activation of IRF3 Kinase IKKÎμ. Journal of Immunology, 2020, 205, 1564-1579.	0.8	30
63	Comparative Transcriptomic Analysis of Rhinovirus and Influenza Virus Infection. Frontiers in Microbiology, 2020, 11, 1580.	3.5	15
64	Metabolic Profiling Reveals Significant Perturbations of Intracellular Glucose Homeostasis in Enterovirus-Infected Cells. Metabolites, 2020, 10, 302.	2.9	9
65	Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: Implications for treatment with IFN- \hat{l}^2 and IFN inducer. Journal of Infection, 2020, 81, e1-e10.	3.3	41
66	A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2. Nature Communications, 2020, 11 , 4252.	12.8	86
67	Viruses harness $Yxx\tilde{A}^{\sim}$ motif to interact with host AP2M1 for replication: A vulnerable broad-spectrum antiviral target. Science Advances, 2020, 6, eaba7910.	10.3	40
68	Quantifying mechanistic traits of influenza viral dynamics using in vitro data. Epidemics, 2020, 33, 100406.	3.0	10
69	Early triple antiviral therapy for COVID-19 – Authors' reply. Lancet, The, 2020, 396, 1488.	13.7	5
70	Nanopore Sequencing Reveals Novel Targets for Detection and Surveillance of Human and Avian Influenza A Viruses. Journal of Clinical Microbiology, 2020, 58, .	3.9	19
71	Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet, The, 2020, 395, 1695-1704.	13.7	1,244
72	Infection of bat and human intestinal organoids by SARS-CoV-2. Nature Medicine, 2020, 26, 1077-1083.	30.7	441

#	Article	IF	CITATIONS
73	Surgical Mask Partition Reduces the Risk of Noncontact Transmission in a Golden Syrian Hamster Model for Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases, 2020, 71, 2139-2149.	5.8	501
74	Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system. Pharmacological Research, 2020, 159, 104960.	7.1	56
75	Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). Viruses, 2020, 12, 628.	3.3	55
76	Attenuated Interferon and Proinflammatory Response in SARS-CoV-2â€"Infected Human Dendritic Cells Is Associated With Viral Antagonism of STAT1 Phosphorylation. Journal of Infectious Diseases, 2020, 222, 734-745.	4.0	165
77	Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated <i>In Vitro</i> and with Clinical Specimens. Journal of Clinical Microbiology, 2020, 58, .	3.9	780
78	Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infectious Diseases, The, 2020, 20, 565-574.	9.1	2,704
79	Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility. Clinical Infectious Diseases, 2020, 71, 2428-2446.	5.8	839
80	Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nature Communications, 2020, 11, 3523.	12.8	357
81	High neutralizing antibody titer in intensive care unit patients with COVID-19. Emerging Microbes and Infections, 2020, 9, 1664-1670.	6.5	129
82	Characterising viable virus from air exhaled by H1N1 influenza-infected ferrets reveals the importance of haemagglutinin stability for airborne infectivity. PLoS Pathogens, 2020, 16, e1008362.	4.7	25
83	Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine, 2020, 382, 1708-1720.	27.0	22,372
84	A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, The, 2020, 395, 514-523.	13.7	7,120
85	Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging Microbes and Infections, 2020, 9, 221-236.	6.5	2,389
86	Competing endogenous RNA network profiling reveals novel host dependency factors required for MERS-CoV propagation. Emerging Microbes and Infections, 2020, 9, 733-746.	6.5	58
87	Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19. Clinical Infectious Diseases, 2020, 71, 1400-1409.	5.8	561
88	Targeting the Inositol-Requiring Enzyme-1 Pathway Efficiently Reverts Zika Virus-Induced Neurogenesis and Spermatogenesis Marker Perturbations. ACS Infectious Diseases, 2020, 6, 1745-1758.	3.8	9
89	Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe, The, 2020, 1, e14-e23.	7.3	683
90	Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission. PLoS Pathogens, 2020, 16, e1008395.	4.7	28

#	Article	IF	CITATIONS
91	Title is missing!. , 2020, 16, e1008395.		0
92	Title is missing!. , 2020, 16, e1008395.		0
93	Title is missing!. , 2020, 16, e1008395.		0
94	Title is missing!. , 2020, 16, e1008395.		0
95	Targeting SUMO Modification of the Non-Structural Protein 5 of Zika Virus as a Host-Targeting Antiviral Strategy. International Journal of Molecular Sciences, 2019, 20, 392.	4.1	19
96	Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling upon Coronavirus Replication. Viruses, 2019, 11, 73.	3.3	228
97	A novel partial lid for mechanical defeatherers reduced aerosol dispersion during processing of avian influenza virus infected poultry. PLoS ONE, 2019, 14, e0216478.	2.5	3
98	Screening of an FDA-Approved Drug Library with a Two-Tier System Identifies an Entry Inhibitor of Severe Fever with Thrombocytopenia Syndrome Virus. Viruses, 2019, 11, 385.	3.3	20
99	Severe acute respiratory syndrome Coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3â€dependent ubiquitination of ASC. FASEB Journal, 2019, 33, 8865-8877.	0.5	434
100	Lipidomic Profiling Reveals Significant Perturbations of Intracellular Lipid Homeostasis in Enterovirus-Infected Cells. International Journal of Molecular Sciences, 2019, 20, 5952.	4.1	27
101	Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines. MBio, 2019, 10, .	4.1	51
102	Prostaglandin E2-Mediated Impairment of Innate Immune Response to A(H1N1)pdm09 Infection in Diet-Induced Obese Mice Could Be Restored by Paracetamol. Journal of Infectious Diseases, 2019, 219, 795-807.	4.0	17
103	SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target. Nature Communications, 2019, 10, 120.	12.8	192
104	Establishment of a lethal aged mouse model of human respiratory syncytial virus infection. Antiviral Research, 2019, 161, 125-133.	4.1	4
105	Identification and characterization of $\langle scp \rangle GLDC \langle scp \rangle$ as host susceptibility gene to severe influenza. EMBO Molecular Medicine, 2019, 11, .	6.9	20
106	Defining the sizes of airborne particles that mediate influenza transmission in ferrets. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2386-E2392.	7.1	71
107	Rhinovirus respiratory tract infection in hospitalized adult patients is associated with T H 2 response irrespective of asthma. Journal of Infection, 2018, 76, 465-474.	3.3	27
108	Inhibitors of Influenza A Virus Polymerase. ACS Infectious Diseases, 2018, 4, 218-223.	3.8	19

#	Article	IF	Citations
109	Large-scale sequence analysis reveals novel human-adaptive markers in PB2 segment of seasonal influenza A viruses. Emerging Microbes and Infections, 2018, 7, 1-12.	6.5	13
110	Immunization With a Novel Human Type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal Models. Journal of Infectious Diseases, 2018, 218, 365-377.	4.0	46
111	Integrated analysis of mRNA-seq and miRNA-seq for host susceptibilities to influenza A (H7N9) infection in inbred mouse lines. Functional and Integrative Genomics, 2018, 18, 411-424.	3.5	6
112	Genetic analysis of H7N9 highly pathogenic avian influenza virus in Guangdong, China, 2016–2017. Journal of Infection, 2018, 76, 93-96.	3.3	12
113	Assessing the risk of downwind spread of avian influenza virus via airborne particles from an urban wholesale poultry market. Building and Environment, 2018, 127, 120-126.	6.9	19
114	The celecoxib derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via down-regulation of the PI3K/Akt pathway and protects Zika virus-infected A129 mice: A host-targeting treatment strategy. Antiviral Research, 2018, 160, 38-47.	4.1	35
115	Co-stimulation With TLR7 Agonist Imiquimod and Inactivated Influenza Virus Particles Promotes Mouse B Cell Activation, Differentiation, and Accelerated Antigen Specific Antibody Production. Frontiers in Immunology, 2018, 9, 2370.	4.8	21
116	Dual-functional peptide with defective interfering genes effectively protects mice against avian and seasonal influenza. Nature Communications, 2018, 9, 2358.	12.8	63
117	Differentiated human airway organoids to assess infectivity of emerging influenza virus. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 6822-6827.	7.1	215
118	Middle East respiratory syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto host cells. Journal of Biological Chemistry, 2018, 293, 11709-11726.	3.4	153
119	Human tryptophanyl-tRNA synthetase is an IFN- $\hat{l}^3\hat{a}$ (inducible entry factor for Enterovirus. Journal of Clinical Investigation, 2018, 128, 5163-5177.	8.2	39
120	Talaromyces marneffei Mp1p Is a Virulence Factor that Binds and Sequesters a Key Proinflammatory Lipid to Dampen Host Innate Immune Response. Cell Chemical Biology, 2017, 24, 182-194.	5.2	26
121	Improved detection of Zika virus <scp>RNA</scp> in human and animal specimens by a novel, highly sensitive and specific realâ€time RTâ€PCR assay targeting the 5′â€untranslated region of Zika virus. Tropical Medicine and International Health, 2017, 22, 594-603.	2.3	34
122	Interplay between SIRT1 and hepatitis B virus X protein in the activation of viral transcription. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2017, 1860, 491-501.	1.9	47
123	Novel antiviral activity and mechanism of bromocriptine as a Zika virus NS2B-NS3 protease inhibitor. Antiviral Research, 2017, 141, 29-37.	4.1	102
124	Structure of the S1 subunit C-terminal domain from bat-derived coronavirus HKU5 spike protein. Virology, 2017, 507, 101-109.	2.4	13
125	Rhinovirus – From bench to bedside. Journal of the Formosan Medical Association, 2017, 116, 496-504.	1.7	64
126	Selective Activation of Type II Interferon Signaling by Zika Virus NS5 Protein. Journal of Virology, 2017, 91, .	3.4	88

#	Article	IF	CITATIONS
127	A tricyclic pyrrolobenzodiazepine produced by Klebsiella oxytoca is associated with cytotoxicity in antibiotic-associated hemorrhagic colitis. Journal of Biological Chemistry, 2017, 292, 19503-19520.	3.4	39
128	A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses. Nature Communications, 2017, 8, 15672.	12.8	115
129	Structure-based discovery of clinically approved drugs as Zika virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus infection inÂvitro and inÂvivo. Antiviral Research, 2017, 145, 33-43.	4.1	99
130	Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Science Advances, 2017, 3, eaao4966.	10.3	317
131	Identification of a novel small-molecule compound targeting the influenza A virus polymerase PB1-PB2 interface. Antiviral Research, 2017, 137, 58-66.	4.1	18
132	PB2 substitutions V598T/I increase the virulence of H7N9 influenza A virus in mammals. Virology, 2017, 501, 92-101.	2.4	34
133	Antibody-Dependent Cell-Mediated Cytotoxicity Epitopes on the Hemagglutinin Head Region of Pandemic $H1N1$ Influenza Virus Play Detrimental Roles in $H1N1$ -Infected Mice. Frontiers in Immunology, 2017, 8, 317.	4.8	32
134	Broad-spectrum inhibition of common respiratory RNA viruses by a pyrimidine synthesis inhibitor with involvement of the host antiviral response. Journal of General Virology, 2017, 98, 946-954.	2.9	53
135	Isolation of H5N6, H7N9 and H9N2 avian influenza A viruses from air sampled at live poultry markets in China, 2014 and 2015. Eurosurveillance, 2016, 21, .	7.0	54
136	A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Scientific Reports, 2016, 6, 22008.	3.3	133
137	Zika fever and congenital Zika syndrome: An unexpected emerging arboviral disease. Journal of Infection, 2016, 72, 507-524.	3.3	215
138	Hemagglutinin of influenza A virus binds specifically to cell surface nucleolin and plays a role in virus internalization. Virology, 2016, 494, 78-88.	2.4	42
139	Novel Mutations L228I and Y232H Cause Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Combinational Pattern. AIDS Research and Human Retroviruses, 2016, 32, 909-917.	1.1	4
140	Middle East respiratory syndrome coronavirus M protein suppresses type I interferon expression through the inhibition of TBK1-dependent phosphorylation of IRF3. Emerging Microbes and Infections, 2016, 5, 1-9.	6.5	108
141	Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 Is an Important Surface Attachment Factor That Facilitates Entry of Middle East Respiratory Syndrome Coronavirus. Journal of Virology, 2016, 90, 9114-9127.	3.4	68
142	Novel residues in the PA protein of avian influenza H7N7 virus affect virulence in mammalian hosts. Virology, 2016, 498, 1-8.	2.4	12
143	Differential cell line susceptibility to the emerging Zika virus: implications for disease pathogenesis, non-vector-borne human transmission and animal reservoirs. Emerging Microbes and Infections, 2016, 5, 1-12.	6.5	139
144	Zika Virus Infection in Dexamethasone-immunosuppressed Mice Demonstrating Disseminated Infection with Multi-organ Involvement Including Orchitis Effectively Treated by Recombinant Type I Interferons. EBioMedicine, 2016, 14, 112-122.	6.1	77

#	Article	IF	Citations
145	Amino acid substitutions V63I or A37S/I61T/V63I/V100A in the PA N-terminal domain increase the virulence of H7N7 influenza A virus. Scientific Reports, 2016, 6, 37800.	3.3	25
146	MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2. Nature Microbiology, 2016, $1,16004$.	13.3	140
147	A novel small-molecule inhibitor of influenza A virus acts by suppressing PA endonuclease activity of the viral polymerase. Scientific Reports, 2016, 6, 22880.	3.3	37
148	A novel small-molecule compound disrupts influenza A virus PB2 cap-binding and inhibits viral replication. Journal of Antimicrobial Chemotherapy, 2016, 71, 2489-2497.	3.0	30
149	Human H7N9 virus induces a more pronounced pro-inflammatory cytokine but an attenuated interferon response in human bronchial epithelial cells when compared with an epidemiologically-linked chicken H7N9 virus. Virology Journal, 2016, 13, 42.	3.4	17
150	Peptide-Mediated Interference of PB2-elF4G1 Interaction Inhibits Influenza A Viruses' Replication in Vitro and in Vivo. ACS Infectious Diseases, 2016, 2, 471-477.	3.8	8
151	Comparative genomic analysis of pre-epidemic and epidemic Zika virus strains for virological factors potentially associated with the rapidly expanding epidemic. Emerging Microbes and Infections, 2016, 5, 1-12.	6.5	162
152	Coronaviruses â€" drug discovery and therapeutic options. Nature Reviews Drug Discovery, 2016, 15, 327-347.	46.4	1,365
153	Identification of Novel Fusion Inhibitors of Influenza A Virus by Chemical Genetics. Journal of Virology, 2016, 90, 2690-2701.	3.4	28
154	Identification of a small-molecule inhibitor of influenza virus via disrupting the subunits interaction of the viral polymerase. Antiviral Research, 2016, 125, 34-42.	4.1	41
155	Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways. Journal of Infectious Diseases, 2016, 213, 904-914.	4.0	379
156	Mycophenolic acid, an immunomodulator, has potent and broad-spectrum in vitro antiviral activity against pandemic, seasonal and avian influenza viruses affecting humans. Journal of General Virology, 2016, 97, 1807-1817.	2.9	59
157	Quantification of Influenza Virus RNA in Aerosols in Patient Rooms. PLoS ONE, 2016, 11, e0148669.	2.5	51
158	PExFInS: An Integrative Post-GWAS Explorer for Functional Indels and SNPs. Scientific Reports, 2015, 5, 17302.	3.3	7
159	Middle East respiratory syndrome coronavirus infection: virus-host cell interactions and implications on pathogenesis. Virology Journal, 2015, 12, 218.	3.4	70
160	Development and Evaluation of Novel Real-Time Reverse Transcription-PCR Assays with Locked Nucleic Acid Probes Targeting Leader Sequences of Human-Pathogenic Coronaviruses. Journal of Clinical Microbiology, 2015, 53, 2722-2726.	3.9	73
161	Complete Genome Sequences of One Human Respiratory Syncytial Antigenic Group A Virus from China and Its Four Mouse-Adapted Isolates. Genome Announcements, 2015, 3, .	0.8	1
162	Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection. Archives of Virology, 2015, 160, 777-786.	2.1	20

#	Article	IF	Citations
163	Transmission of H7N9 Influenza Viruses with a Polymorphism at PB2 Residue 627 in Chickens and Ferrets. Journal of Virology, 2015, 89, 9939-9951.	3.4	26
164	Host genes and influenza pathogenesis in humans: an emerging paradigm. Current Opinion in Virology, 2015, 14, 7-15.	5.4	25
165	Treatment With Lopinavir/Ritonavir or Interferon- \hat{l}^2 1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. Journal of Infectious Diseases, 2015, 212, 1904-1913.	4.0	572
166	Functional variants regulating LGALS1 (Galectin 1) expression affect human susceptibility to influenza A(H7N9). Scientific Reports, 2015, 5, 8517.	3.3	43
167	Identification of <i>TMPRSS2 </i> as a Susceptibility Gene for Severe 2009 Pandemic A(H1N1) Influenza and A(H7N9) Influenza. Journal of Infectious Diseases, 2015, 212, 1214-1221.	4.0	170
168	Middle East Respiratory Syndrome Coronavirus: Another Zoonotic Betacoronavirus Causing SARS-Like Disease. Clinical Microbiology Reviews, 2015, 28, 465-522.	13.6	703
169	Cross-Protection of Influenza A Virus Infection by a DNA Aptamer Targeting the PA Endonuclease Domain. Antimicrobial Agents and Chemotherapy, 2015, 59, 4082-4093.	3.2	38
170	Cross-species transmission and emergence of novel viruses from birds. Current Opinion in Virology, 2015, 10, 63-69.	5.4	74
171	Suboptimal Humoral Immune Response against Influenza A(H7N9) Virus Is Related to Its Internal Genes. Vaccine Journal, 2015, 22, 1235-1243.	3.1	19
172	Ebola virus disease: a highly fatal infectious disease reemerging in West Africa. Microbes and Infection, 2015, 17, 84-97.	1.9	35
173	Avian Influenza A H7N9 Virus Induces Severe Pneumonia in Mice without Prior Adaptation and Responds to a Combination of Zanamivir and COX-2 Inhibitor. PLoS ONE, 2014, 9, e107966.	2.5	35
174	Surfactant Protein B Gene Polymorphism Is Associated With Severe Influenza. Chest, 2014, 145, 1237-1243.	0.8	47
175	Requirement of CRTC1 coactivator for hepatitis B virus transcription. Nucleic Acids Research, 2014, 42, 12455-12468.	14.5	23
176	The K526R substitution in viral protein PB2 enhances the effects of E627K on influenza virus replication. Nature Communications, 2014, 5, 5509.	12.8	155
177	An Animal Model of MERS Produced by Infection of Rhesus Macaques With MERS Coronavirus. Journal of Infectious Diseases, 2014, 209, 236-242.	4.0	111
178	Viral lung infections. Current Opinion in Pulmonary Medicine, 2014, 20, 225-232.	2.6	31
179	Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein. Science Translational Medicine, 2014, 6, 234ra59.	12.4	194
180	Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. Virology, 2014, 454-455, 197-205.	2.4	149

#	Article	IF	Citations
181	Active Replication of Middle East Respiratory Syndrome Coronavirus and Aberrant Induction of Inflammatory Cytokines and Chemokines in Human Macrophages: Implications for Pathogenesis. Journal of Infectious Diseases, 2014, 209, 1331-1342.	4.0	369
182	Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nature Communications, 2014, 5, 3067.	12.8	324
183	Emergence in China of human disease due to avian influenza A(H10N8) – Cause for concern?. Journal of Infection, 2014, 68, 205-215.	3.3	106
184	Immunogenicity of Intradermal Trivalent Influenza Vaccine With Topical Imiquimod: A Double Blind Randomized Controlled Trial. Clinical Infectious Diseases, 2014, 59, 1246-1255.	5.8	77
185	Middle East Respiratory Syndrome Coronavirus 4a Protein Is a Double-Stranded RNA-Binding Protein That Suppresses PACT-Induced Activation of RIG-I and MDA5 in the Innate Antiviral Response. Journal of Virology, 2014, 88, 4866-4876.	3.4	171
186	Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends in Microbiology, 2013, 21, 544-555.	7.7	461
187	Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. Journal of General Virology, 2013, 94, 2679-2690.	2.9	347
188	Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. Journal of Infection, 2013, 67, 606-616.	3.3	314
189	Receptor binding and transmission studies of H5N1 influenza virus in mammals. Emerging Microbes and Infections, 2013, 2, 1-5.	6.5	15
190	The emergence of influenza A H7N9 in human beings 16 years after influenza A H5N1: a tale of two cities. Lancet Infectious Diseases, The, 2013, 13, 809-821.	9.1	129
191	Clinical, Virological, and Histopathological Manifestations of Fatal Human Infections by Avian Influenza A(H7N9) Virus. Clinical Infectious Diseases, 2013, 57, 1449-1457.	5.8	102
192	Prioritizing genes responsible for host resistance to influenza using network approaches. BMC Genomics, 2013, 14, 816.	2.8	3
193	Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. Journal of Infection, 2013, 67, 130-140.	3.3	158
194	Genetic Characterization of Betacoronavirus Lineage C Viruses in Bats Reveals Marked Sequence Divergence in the Spike Protein of Pipistrellus Bat Coronavirus HKU5 in Japanese Pipistrelle: Implications for the Origin of the Novel Middle East Respiratory Syndrome Coronavirus. Journal of Virology, 2013, 87, 8638-8650.	3.4	225
195	Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet, The, 2013, 381, 1916-1925.	13.7	781
196	Leptin Mediates the Pathogenesis of Severe 2009 Pandemic Influenza A(H1N1) Infection Associated With Cytokine Dysregulation in Mice With Diet-Induced Obesity. Journal of Infectious Diseases, 2013, 207, 1270-1280.	4.0	102
197	Differential Cell Line Susceptibility to the Emerging Novel Human Betacoronavirus 2c EMC/2012: Implications for Disease Pathogenesis and Clinical Manifestation. Journal of Infectious Diseases, 2013, 207, 1743-1752.	4.0	195
198	Use of Nasopharyngeal Aspirate for Diagnosis of Pneumocystis Pneumonia. Journal of Clinical Microbiology, 2013, 51, 1570-1574.	3.9	28

#	Article	IF	CITATIONS
199	Hyperimmune IV Immunoglobulin Treatment. Chest, 2013, 144, 464-473.	0.8	269
200	From SARS coronavirus to novel animal and human coronaviruses. Journal of Thoracic Disease, 2013, 5 Suppl 2, S103-8.	1.4	63
201	A Functional Variation in CD55 Increases the Severity of 2009 Pandemic H1N1 Influenza A Virus Infection. Journal of Infectious Diseases, 2012, 206, 495-503.	4.0	79
202	Feline morbillivirus, a previously undescribed paramyxovirus associated with tubulointerstitial nephritis in domestic cats. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5435-5440.	7.1	150
203	High Titer and Avidity of Nonneutralizing Antibodies against Influenza Vaccine Antigen Are Associated with Severe Influenza. Vaccine Journal, 2012, 19, 1012-1018.	3.1	82
204	Avian influenza A H5N1 virus: a continuous threat to humans. Emerging Microbes and Infections, 2012, $1,1\text{-}12.$	6.5	76
205	Anti-ganglioside antibodies were not detected in human subjects infected with or vaccinated against 2009 pandemic influenza A (H1N1) virus. Vaccine, 2012, 30, 2605-2610.	3.8	13
206	Two Years after Pandemic Influenza A/2009/H1N1: What Have We Learned?. Clinical Microbiology Reviews, 2012, 25, 223-263.	13.6	182
207	Genetic relatedness of the novel human group C betacoronavirus to <i>Tylonycteris</i> bat coronavirus HKU4 and <i>Pipistrellus</i> bat coronavirus HKU5. Emerging Microbes and Infections, 2012, 1, 1-5.	6.5	93
208	Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic?. Journal of Infection, 2012, 65, 477-489.	3.3	147
209	The Management of the 2009 pandemic Influenza A H1N1 virus infection. Journal of Thoracic Disease, 2012, 4, 4-6.	1.4	21
210	Structural basis and sequence co-evolution analysis of the hemagglutinin protein of pandemic influenza A/H1N1 (2009) virus. Experimental Biology and Medicine, 2011, 236, 915-925.	2.4	15
211	A Recombinant Vaccine of H5N1 HA1 Fused with Foldon and Human IgG Fc Induced Complete Cross-Clade Protection against Divergent H5N1 Viruses. PLoS ONE, 2011, 6, e16555.	2.5	37
212	CL-385319 inhibits H5N1 avian influenza A virus infection by blocking viral entry. European Journal of Pharmacology, 2011, 660, 460-467.	3.5	59
213	$Kr\tilde{A}\frac{1}{4}$ ppel-like factor 15 activates hepatitis B virus gene expression and replication. Hepatology, 2011, 54, 109-121.	7.3	25
214	A critical role of IL-17 in modulating the B-cell response during H5N1 influenza virus infection. Cellular and Molecular Immunology, 2011, 8, 462-468.	10.5	88
215	Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection. Clinical Infectious Diseases, 2011, 52, 447-456.	5.8	596
216	The Lower Serum Immunoglobulin G2 Level in Severe Cases than in Mild Cases of Pandemic H1N1 2009 Influenza Is Associated with Cytokine Dysregulation. Vaccine Journal, 2011, 18, 305-310.	3.1	58

#	Article	IF	CITATIONS
217	High Incidence of Severe Influenza among Individuals over 50 Years of Age. Vaccine Journal, 2011, 18, 1918-1924.	3.1	27
218	The Natural Viral Load Profile of Patients With Pandemic 2009 Influenza A(H1N1) and the Effect of Oseltamivir Treatment. Chest, 2010, 137, 759-768.	0.8	99
219	Viral load in patients infected with pandemic H1N1 2009 influenza A virus. Journal of Medical Virology, 2010, 82, 1-7.	5.0	200
220	Association of candidate susceptible loci with chronic infection with hepatitis B virus in a Chinese population. Journal of Medical Virology, 2010, 82, 371-378.	5.0	50
221	Identification of influenza A nucleoprotein as an antiviral target. Nature Biotechnology, 2010, 28, 600-605.	17.5	234
222	Concurrent comparison of epidemiology, clinical presentation and outcome between adult patients suffering from the pandemic influenza A (H1N1) 2009 virus and the seasonal influenza A virus infection. Postgraduate Medical Journal, 2010, 86, 515-521.	1.8	55
223	Quasispecies of the D225G Substitution in the Hemagglutinin of Pandemic Influenza A(H1N1) 2009 Virus from Patients with Severe Disease in Hong Kong, China. Journal of Infectious Diseases, 2010, 201, 1517-1521.	4.0	99
224	Effect of Clinical and Virological Parameters on the Level of Neutralizing Antibody against Pandemic Influenza A Virus H1N1 2009. Clinical Infectious Diseases, 2010, 51, 274-279.	5.8	70
225	Ecoepidemiology and Complete Genome Comparison of Different Strains of Severe Acute Respiratory Syndrome-Related <i>Rhinolophus</i> Bat Coronavirus in China Reveal Bats as a Reservoir for Acute, Self-Limiting Infection That Allows Recombination Events. Journal of Virology, 2010, 84, 2808-2819.	3.4	242
226	Coexistence of Different Genotypes in the Same Bat and Serological Characterization of <i>Rousettus</i> Bat Coronavirus HKU9 Belonging to a Novel <i>Betacoronavirus</i> Subgroup. Journal of Virology, 2010, 84, 11385-11394.	3.4	102
227	Cytokine Profiles Induced by the Novel Swineâ€Origin Influenza A/H1N1 Virus: Implications for Treatment Strategies. Journal of Infectious Diseases, 2010, 201, 346-353.	4.0	125
228	Delayed Clearance of Viral Load and Marked Cytokine Activation in Severe Cases of Pandemic H1N1 2009 Influenza Virus Infection. Clinical Infectious Diseases, 2010, 50, 850-859.	5.8	403
229	D225G mutation in hemagglutinin of pandemic influenza H1N1 (2009) virus enhances virulence in mice. Experimental Biology and Medicine, 2010, 235, 981-988.	2.4	99
230	Wild Type and Mutant 2009 Pandemic Influenza A (H1N1) Viruses Cause More Severe Disease and Higher Mortality in Pregnant BALB/c Mice. PLoS ONE, 2010, 5, e13757.	2.5	86
231	Small Interfering RNA Targeting M2 Gene Induces Effective and Long Term Inhibition of Influenza A Virus Replication. PLoS ONE, 2009, 4, e5671.	2.5	60
232	Confirmation of the First Hong Kong Case of Human Infection by Novel Swine Origin Influenza A (H1N1) Virus Diagnosed Using Ultrarapid, Real-Time Reverse Transcriptase PCR. Journal of Clinical Microbiology, 2009, 47, 2344-2346.	3.9	39
233	Severe Acute Respiratory Syndrome Coronavirus M Protein Inhibits Type I Interferon Production by Impeding the Formation of TRAF3·TANK·TBK1/IKKϵ Complex. Journal of Biological Chemistry, 2009, 284, 16202-16209.	3.4	261
234	Oseltamivir-Resistant Influenza A Pandemic (H1N1) 2009 Virus, Hong Kong, China. Emerging Infectious Diseases, 2009, 15, 1970-1972.	4.3	92

#	Article	IF	CITATIONS
235	Identification of Major Histocompatibility Complex Class I C Molecule as an Attachment Factor That Facilitates Coronavirus HKU1 Spike-Mediated Infection. Journal of Virology, 2009, 83, 1026-1035.	3.4	35
236	A regulatory polymorphism in interferon- \hat{l}^3 receptor 1 promoter is associated with the susceptibility to chronic hepatitis B virus infection. Immunogenetics, 2009, 61, 423-430.	2.4	31
237	A nonâ€synonymous single nucleotide polymorphism in IFNAR1 affects susceptibility to chronic hepatitis B virus infection. Journal of Viral Hepatitis, 2009, 16, 45-52.	2.0	34
238	Crystal structure of an avian influenza polymerase PAN reveals an endonuclease active site. Nature, 2009, 458, 909-913.	27.8	437
239	Coronavirus Diversity, Phylogeny and Interspecies Jumping. Experimental Biology and Medicine, 2009, 234, 1117-1127.	2.4	548
240	Functional dissection of an IFN- $\hat{l}\pm/\hat{l}^2$ receptor 1 promoter variant that confers higher risk to chronic hepatitis B virus infection. Journal of Hepatology, 2009, 51, 322-332.	3.7	28
241	Crystal structure of the polymerase PAC–PB1N complex from an avian influenza H5N1 virus. Nature, 2008, 454, 1123-1126.	27.8	248
242	Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8091-8096.	7.1	280
243	Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection. Journal of Immunology. 2008, 180, 948-956.	0.8	124
244	Comparative Analysis of Twelve Genomes of Three Novel Group 2c and Group 2d Coronaviruses Reveals Unique Group and Subgroup Features. Journal of Virology, 2007, 81, 1574-1585.	3.4	233
245	Polymorphisms of type I interferon receptor 1 promoter and their effects on chronic hepatitis B virus infection. Journal of Hepatology, 2007, 46, 198-205.	3.7	41
246	Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines. Virology, 2006, 353, 6-16.	2.4	41
247	Modulation of the Unfolded Protein Response by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein. Journal of Virology, 2006, 80, 9279-9287.	3.4	202
248	Cytokine Responses in Severe Acute Respiratory Syndrome Coronavirus-Infected Macrophages In Vitro: Possible Relevance to Pathogenesis. Journal of Virology, 2005, 79, 7819-7826.	3.4	394
249	Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E. Journal of General Virology, 2005, 86, 1423-1434.	2.9	215
250	Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region. Journal of Virology, 2005, 79, 2678-2688.	3.4	188
251	Avian Influenza A (H5N1) Infection in Humans. New England Journal of Medicine, 2005, 353, 1374-1385.	27.0	1,235
252	Characterization and Complete Genome Sequence of a Novel Coronavirus, Coronavirus HKU1, from Patients with Pneumonia. Journal of Virology, 2005, 79, 884-895.	3.4	1,269

#	Article	IF	CITATIONS
253	Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14040-14045.	7.1	1,322
254	Sensitive and Specific Monoclonal Antibody-Based Capture Enzyme Immunoassay for Detection of Nucleocapsid Antigen in Sera from Patients with Severe Acute Respiratory Syndrome. Journal of Clinical Microbiology, 2004, 42, 2629-2635.	3.9	126
255	Selective functional deficit in dendritic cell - T cell interaction is a crucial mechanism in chronic hepatitis B virus infection. Journal of Viral Hepatitis, 2004, 11, 217-224.	2.0	71
256	Identification of Novel Small-Molecule Inhibitors of Severe Acute Respiratory Syndrome-Associated Coronavirus by Chemical Genetics. Chemistry and Biology, 2004, 11, 1293-1299.	6.0	141
257	Therapeutic efficacy of hepatitis B surface antigen–antibodies-recombinant DNA composite in HBsAg transgenic mice. Vaccine, 2001, 19, 4219-4225.	3.8	55
258	Rock1 is a novel host dependency factor of human enterovirus A71: Implication as a drug target. Journal of Medical Virology, $0, , .$	5.0	4